Robert Petryka
Overview
Explore the profile of Robert Petryka including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
281
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sandborn W, Rutgeerts P, Colombel J, Ghosh S, Petryka R, Sands B, et al.
J Crohns Colitis
. 2017 Mar;
11(7):811-819.
PMID: 28333187
Background And Aims: This 11-week Phase IIa induction study evaluated the efficacy and safety of eldelumab in patients with active Crohn's disease. Methods: Adults with Crohn's Disease Activity Index 220-450...
2.
Vermeire S, Schreiber S, Petryka R, Kuehbacher T, Hebuterne X, Roblin X, et al.
Lancet
. 2016 Dec;
389(10066):266-275.
PMID: 27988142
Background: Filgotinib (GLPG0634, GS-6034) is a once-daily, orally administered, Janus kinase 1 (JAK1)-selective inhibitor. The FITZROY study examined the efficacy and safety of filgotinib for the treatment of moderate-to-severe Crohn's...
3.
Milek T, Baranowski K, Petryka R, Ciostek P
Surg Laparosc Endosc Percutan Tech
. 2016 Nov;
26(6):473-475.
PMID: 27846166
In Conclusion: (1) the use of interventional radiology methods in the closure of pancreatic fistula is an effective and safe procedure; and (2) the recurrence of fistula is dependent on...
4.
Allez M, Skolnick B, Wisniewska-Jarosinska M, Petryka R, Overgaard R
Gut
. 2016 Aug;
66(11):1918-1925.
PMID: 27489241
Objective: Anti-NKG2D (NNC0142-0002) is an antagonising human immunoglobulin G4 monoclonal antibody that binds to natural killer group 2 member D (NKG2D) receptors, which are expressed by T cells and innate...
5.
Atreya R, Bloom S, Scaldaferri F, Gerardi V, Admyre C, Karlsson A, et al.
J Crohns Colitis
. 2016 May;
10(11):1294-1302.
PMID: 27208386
Background And Aims: Toll-like receptors [TLRs] are potential drug targets for immunomodulation. We determined the safety and efficacy of the TLR-9 agonist DNA-based immunomodulatory sequence 0150 [DIMS0150] in ulcerative colitis...
6.
Milek T, Ciostek P, Petryka R, Slowik J, Jarosz M
Wideochir Inne Tech Maloinwazyjne
. 2016 Feb;
10(4):515-20.
PMID: 26865886
Introduction: Intestinal fistulas occur in 4-8% of cases of upper gastrointestinal tract surgery. Until now, surgery has been the standard of treating fistulas in oesophagointestinal anastomosis. The use of stents...
7.
Milek T, Ciostek P, Kielar M, Jarosz M, Slowik K, Petryka R, et al.
Turk J Gastroenterol
. 2014 Jun;
25(1):59-62.
PMID: 24918132
Background/aims: The aim of this study was to compare the surgical drainage of large, symptomatic pancreatic cysts (>5 cm) with single- and multi-channel endoscopic drainage. Materials And Methods: In the...
8.
Keshav S, Vanasek T, Niv Y, Petryka R, Howaldt S, Bafutto M, et al.
PLoS One
. 2013 Mar;
8(3):e60094.
PMID: 23527300
Unlabelled: CCX282-B, also called vercirnon, is a specific, orally-administered chemokine receptor CCR9 antagonist that regulates migration and activation of inflammatory cells in the intestine. This randomized, placebo-controlled trial was conducted...